Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.

Hélène BabeyPhilippe JammeHubert CurcioJean Baptiste AssiéRemi VeillonHélène DoubreMaurice PérolFlorian GuisierEric HuchotChantal DecroisetteLionel FalcheroRomain CorreAlexis CortotChristos ChouaidRenaud Descourt

Published in: Targeted oncology (2023)

In this real-life study, there was no evidence of benefit in mOS with anti-MET TKIs.

Keyphrases

tyrosine kinase
room temperature
gold nanoparticles
highly efficient
reduced graphene oxide